Wenzhou Kangning Hospital Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Wenzhou Kangning Hospital.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	18.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Share Price Matching Investor Opinion

Sep 26

We Think The Compensation For Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) CEO Looks About Right

May 23

Estimating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)

Feb 28

Investors Continue Waiting On Sidelines For Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)

Jan 19

Returns On Capital Are Showing Encouraging Signs At Wenzhou Kangning Hospital (HKG:2120)

Aug 11

Calculating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)

Jul 09

Wenzhou Kangning Hospital (HKG:2120) Is Experiencing Growth In Returns On Capital

May 12

Wenzhou Kangning Hospital (HKG:2120) Has A Pretty Healthy Balance Sheet

Apr 10

Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Feb 25

Will Wenzhou Kangning Hospital (HKG:2120) Multiply In Value Going Forward?

Jan 17

Should You Use Wenzhou Kangning Hospital's (HKG:2120) Statutory Earnings To Analyse It?

Dec 23

If You Had Bought Wenzhou Kangning Hospital's (HKG:2120) Shares Five Years Ago You Would Be Down 42%

Dec 10

Can Mixed Fundamentals Have A Negative Impact on Wenzhou Kangning Hospital Co., Ltd. (HKG:2120) Current Share Price Momentum?

Nov 27

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wenzhou Kangning Hospital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2120 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,647	93	85	268	N/A
3/31/2024	1,622	89	85	267	N/A
12/31/2023	1,596	86	85	265	N/A
9/30/2023	1,560	33	73	275	N/A
6/30/2023	1,525	-19	61	285	N/A
3/31/2023	1,505	-22	26	256	N/A
12/31/2022	1,485	-24	-10	227	N/A
9/30/2022	1,456	12	-7	220	N/A
6/30/2022	1,428	48	-4	213	N/A
3/31/2022	1,363	46	6	203	N/A
12/31/2021	1,297	44	15	194	N/A
9/30/2021	1,207	45	15	207	N/A
6/30/2021	1,132	54	15	219	N/A
3/31/2021	1,060	55	13	209	N/A
12/31/2020	989	56	12	200	N/A
9/30/2020	968	49	3	162	N/A
6/30/2020	947	42	-7	125	N/A
3/31/2020	904	49	-11	118	N/A
12/31/2019	861	57	-16	111	N/A
9/30/2019	814	74	-48	78	N/A
6/30/2019	768	91	-79	45	N/A
3/31/2019	757	86	-79	56	N/A
12/31/2018	746	81	-79	67	N/A
9/30/2018	743	73	N/A	N/A	N/A
6/30/2018	740	65	-31	103	N/A
3/31/2018	703	57	N/A	92	N/A
12/31/2017	666	49	N/A	81	N/A
9/30/2017	588	58	N/A	N/A	N/A
6/30/2017	509	67	N/A	15	N/A
3/31/2017	462	68	N/A	33	N/A
12/31/2016	415	69	N/A	50	N/A
9/30/2016	394	62	N/A	48	N/A
6/30/2016	373	55	N/A	47	N/A
3/31/2016	358	55	N/A	21	N/A
12/31/2015	344	56	N/A	-5	N/A
9/30/2015	332	56	N/A	6	N/A
6/30/2015	319	56	N/A	17	N/A
3/31/2015	308	54	N/A	25	N/A
12/31/2014	296	51	N/A	33	N/A
12/31/2013	226	36	N/A	37	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2120's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2120's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2120's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2120's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2120's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2120's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 21:27
End of Day Share Price	2024/12/24 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Wenzhou Kangning Hospital Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ruili Bian	Citigroup Inc
Ying Shao	CLSA
Sze Chuen Tam	Core Pacific -Yamaichi International (H.K.) Limited

Wenzhou Kangning Hospital Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Wenzhou Kangning Hospital Co., Ltd. Approves Interim Dividend for the Six Months Ended June 30, 2024, Payable on November 18, 2024

Upcoming dividend of CN¥0.15 per share

First half 2024 earnings released: EPS: CN¥0.68 (vs CN¥0.59 in 1H 2023)

First half dividend of CN¥0.15 announced

Investor sentiment deteriorates as stock falls 15%

Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Share Price Matching Investor Opinion

First half 2024 earnings released

Wenzhou Kangning Hospital Co., Ltd. Proposes Interim Dividend for the Six Months Ended June 30, 2024

Wenzhou Kangning Hospital Co., Ltd. Proposes Interim Dividend for the Six Months Ended June 30, 2024

Wenzhou Kangning Hospital Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Vice GM recently bought HK$96k worth of stock

Upcoming dividend of CN¥0.30 per share

We Think The Compensation For Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) CEO Looks About Right

Wenzhou Kangning Hospital Co., Ltd., Annual General Meeting, May 30, 2024

New minor risk - Dividend sustainability

Full year 2023 earnings released

Wenzhou Kangning Hospital Co., Ltd. Proposes Final Dividend for the Year Ended December 31, 2023 Payable on 28 June 2024

New minor risk - Financial data availability

Wenzhou Kangning Hospital Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Estimating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)

New minor risk - Market cap size

Investors Continue Waiting On Sidelines For Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)

Wenzhou Kangning Hospital (HKG:2120) Has A Somewhat Strained Balance Sheet

Wenzhou Kangning Hospital Co., Ltd. Approves Interim Dividend for the Six Months Ended June 30, 2023, Payable on 10 November 2023

Upcoming dividend of HK$0.11 per share at 1.8% yield

Wenzhou Kangning Hospital Co., Ltd. Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 30 November 2023

Vice GM recently bought HK$349k worth of stock

First half 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.52 in 1H 2022)

Wenzhou Kangning Hospital Co., Ltd. Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 30 November 2023

New minor risk - Market cap size

Wenzhou Kangning Hospital (HKG:2120) Could Be Struggling To Allocate Capital

Wenzhou Kangning Hospital Co., Ltd. Approves Board Changes

New major risk - Revenue and earnings growth

Less than half of directors are independent

Wenzhou Kangning Hospital Co., Ltd., Annual General Meeting, Jun 09, 2023

Wenzhou Kangning Hospital Co., Ltd. to Report First Half, 2022 Results on Jan 10, 2023

Wenzhou Kangning Hospital Co., Ltd., Annual General Meeting, Dec 16, 2022

Wenzhou Kangning Hospital Co., Ltd. to Report Fiscal Year 2021 Results on Oct 14, 2022

Wenzhou Kangning Hospital Co., Ltd. Announces Resignation of Ms. Wang Hongyue as Executive Director

Wenzhou Kangning Hospital Co., Ltd. Announces Management Changes

Returns Are Gaining Momentum At Wenzhou Kangning Hospital (HKG:2120)

Wenzhou Kangning Hospital Co., Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment deteriorated over the past week

Wenzhou Kangning Hospital Co., Ltd. Announces Resignation of Sun Fangjun as Chairman of the Supervisory Committee, Effective February 15, 2022

Investor sentiment deteriorated over the past week

Wenzhou Kangning Hospital Co., Ltd. (SEHK:2120) entered into an equity acquisition agreement to acquire Yueqing Bang-er Chinese & Western Medicine Hospital Limited from Zhejiang Boner Medical Investment Management Co., Ltd. for CNY 43.7 million.

Investor sentiment deteriorated over the past week

Is Wenzhou Kangning Hospital (HKG:2120) Using Too Much Debt?

First half 2021 earnings released: EPS CN¥0.59 (vs CN¥0.50 in 1H 2020)

Insider recently sold HK$2.4m worth of stock

Investor sentiment improved over the past week

Non-Executive Director Yang Yang has left the company

Shareholder Representative Supervisor Jingou Huang has left the company

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.59 (vs CN¥0.50 in 1H 2020)

Returns On Capital Are Showing Encouraging Signs At Wenzhou Kangning Hospital (HKG:2120)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Wenzhou Kangning Hospital (HKG:2120) Is Experiencing Growth In Returns On Capital

Full year 2020 earnings released: EPS CN¥0.97 (vs CN¥0.78 in FY 2019)

Insider recently bought HK$9.6m worth of stock

Wenzhou Kangning Hospital (HKG:2120) Has A Pretty Healthy Balance Sheet

Full year 2020 earnings released: EPS CN¥0.97 (vs CN¥0.78 in FY 2019)

Wenzhou Kangning Hospital Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: HK$24.95

Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

New 90-day high: HK$30.70

Will Wenzhou Kangning Hospital (HKG:2120) Multiply In Value Going Forward?

Should You Use Wenzhou Kangning Hospital's (HKG:2120) Statutory Earnings To Analyse It?

New 90-day high: HK$27.30

If You Had Bought Wenzhou Kangning Hospital's (HKG:2120) Shares Five Years Ago You Would Be Down 42%